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Digoxin and diuretics have been used for centuries to treat
the symptoms of heart failure. Yet, it was the addition of
angiotensin-converting enzyme (ACE) inhibitors that revo-
lutionized the management of chronic heart failure by
demonstrating an astonishing 40% reduction in 6-month
mortality when compared to placebo in the original
CONSENSUS (Cooperative North Scandinavian Enalapril
Survival Study) (1). The evolution of evidence-based therapies
makes it difﬁcult to study new treatments without established
background therapy. Thus, beta-blockers were studied in
patients already treatedwithACE inhibitors; other drugs such
as angiotensin receptor antagonists and the combination of
hydralazine and isosorbide dinitrate were studied in patientsSee page 1585already treated with ACE inhibitors and beta-blockers. As
a result of this evolution of evidence-based therapies, heart
failure patients are now treated with a cocktail of medications
often including ACE inhibitors, beta-blockers, digoxin,
diuretics, aspirin, statins, and in some cases hydralazine and
isosorbide dinitrate. These medications, in addition to med-
ications used to treat concomitant conditions such as coronary
artery disease, diabetes, and kidney disease, add to the expense
of therapy and increase the likelihood for drug interactions,
drug-related adverse effects (AEs), and noncompliance.
Mineralocorticoid receptor antagonists (MRAs), added to
standard heart failure medications, reduce morbidity and
mortality in patients with reduced ejection fraction and New
York Heart Association (NYHA) functional class II to IV
heart failure (RALES [Randomized Aldactone Evaluation
Study] and EMPHASIS-HF [Eplerenone in Mild Patients
Hospitalization and Survival Study in Heart Failure]) (2,3)
and in patients with acute heart failure following myocar-
dial infarction (EPHUSUS [Eplerenone Post–Acute
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trials, the use of MRAs in the treatment of heart failure with
reduced ejection fraction (HFrEF) has not been widely
adopted. The relevance of the RALES trial has been ques-
tioned because this study was done prior to the widespread
use of beta-blockers and included only patients with
advanced heart failure. Furthermore, clinicians became
concerned about the safe use of MRAs in the general patient
population when reports of excess hospitalizations for
hyperkalemia and deaths were temporally linked to increased
prescriptions of spironolactone in Ontario, Canada (5)
following publication of the RALES trial. These concerns,
along with patients’ and providers’ reluctance to “pile on
another medication” have impeded the rapid addition of
MRAs to the standard drug regimen for HFrEF.
In this issue of the Journal, Eschalier et al. (6) present
a compelling subgroup analysis of the EMPHASIS-HF trial
examining the use of the MRA epleronone in patients with
HFrEF and NYHA functional class II heart failure symp-
toms. We now must face yet another challenge posed by the
incremental nature of evidence-based therapies: Is it time to
encourage all symptomatic heart failure patients to addMRAs
to their list of medications? In the overall EMPHASIS-HF
trial, epleronone reduced the combined endpoint of hospi-
talization for heart failure or cardiovascular mortality (the
primary endpoint) by 37% (3). In the current substudy, the
effect of epleronone on safety and outcomes were examined in
patients commonly felt to be at highest risk for drug-related
complications including subjects older than 75 years, with
glomerular ﬁltration rate<60 ml/min/1.73 m2, diabetes, and
systolic blood pressure >123 mm Hg (the median systolic
blood pressure in the EMPHASIS-HF trial). Eplerenone
reduced the primary endpoint in all of the prespeciﬁed high-
risk subgroups with convincing statistical signiﬁcance. There
was a signiﬁcant increase in the incidence of hyperkalemia
(K>5.5 mmol/l) in all high-risk subgroups but no increase in
the incidence of severe hyperkalemia (>6.0 mmol/l), hospi-
talization for hyperkalemia, hyperkalemia leading to drug
discontinuation, or hospitalization for worsening renal func-
tion. The authors conclude that there is compelling data for
the use of eplerenone in carefully selected high-risk patients
with NYHA functional class II HFrEF.
What should the clinician do now? This substudy of
EMPHASIS-HF gives us new and compelling data to
consider. The authors have shown that eplerenone is effective
at reducing hospitalization for heart failure and cardiovas-
cular mortality not only in aggregate among study partici-
pants, but also in patients representing high-risk subgroups.
More interesting, however, the safety data suggest that there
is not an increase in serious AEs including severe hyper-
kalemia and worsening renal function. At face value, these
data imply that the predominance of patients with mild heart
failure should be treated with MRAs.
However, there are several very important caveats. First,
patients at highest risk for drug-related adverse events were
excluded from the EMPHASIS-HF trial. Exclusion criteria
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sium >5.0 mmol/l, estimated glomerular ﬁltration rate <30
ml/min/1.73 m2 and any other clinically signiﬁcant comor-
bidities including mental illness, alcohol or chemical
dependency, pre-existing liver disease, or the use of cyto-
chrome P450 CYP 3A4 inducers or inhibitors. Second, the
trial had a reduced dosing protocol for patients with chronic
kidney disease (speciﬁcally those with an estimated glomer-
ular ﬁltration rate between 30 and 49 ml/min/1.73 m2).
Finally, the laboratory monitoring protocol was very struc-
tured involving serum potassium assessments after every dose
adjustment, and every 4 months thereafter. Dose adjustments
were required whenever the potassium was 5.5 to 5.9 mmol/l
and drug was discontinued if the potassium was6.0 mmol/l,
only to be restarted if the potassium on repeat testing
was <5.0 mmol/l.
Therefore, we conclude that MRA therapy is an impor-
tant addition to standard background therapy for stable, very
carefully selected NYHA functional class II heart failure
patients with an ejection fraction of 30% (35% or less if the
QRS duration is >130 ms), treated with an ACE inhibitor
or an angiotensin receptor blocker and a beta-blocker, unless
contraindicated, at the recommended or maximally tolerated
doses. All such patients should be part of an ongoing
provider–patient relationship in an ambulatory care setting
with robust mechanisms in place to closely follow patients
for drug-related AEs. Outpatient tracking systems to ensure
proper monitoring and dose adjustment should be manda-
tory prior to initiating therapy; electronic health records
equipped with decision support and automated providernotiﬁcations may facilitate the safe implementation of
MRA therapy. Because real-life clinical practice is ﬁlled with
both human- and systems-related variables, we recommend
careful case selection and monitoring before initiating MRA
therapy.
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